BIA Networking Lunch - Stevenage

Register today for another popular networking lunch, hosted by Stevenage Bioscience Catalyst. This is a great opportunity to hear from local members, meet new business contacts and grab a bite to eat. We are excited to be showcasing members the Stevenage region.


12.00 - 13.00 - Registration, networking and lunch

13.00 - 14.00 - Talks and discussion

14.00 - 14.30 - Further networking


Stevenage Bioscience Catalyst
Gunnels Wood Rd


Free for members and non-members


Steve Bates

Chief Executive Officer


Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.

Dr Sally Ann Forsyth

Chief Executive Officer

Stevenage Bioscience Catalyst

Sally Ann has been responsible for the strategy, growth and development of 4 internationally recognised science parks including Harwell Oxford (STFC), Colworth Science Park (Unilever), Norwich Research Park (BBSRC) and most recently Stevenage Bioscience Catalyst (GSK/Wellcome). She began her career with Unilever as part of the management training scheme and later had lead responsibility for In-Licensing, Strategic Alliances and Open Innovation within the Unilever Foods and Discovery divisions. Being part of the founding team of Unilever Ventures and Unilever Technology Ventures gave Sally Ann an insight into the needs of growing companies. She gained her property experience through Goodman International where she was Director of Science Parks responsible for the development and management of their UK portfolio.

Sally Ann is passionate about the translation of UK science into world leading innovations and the creation of supportive environments to help early stage companies grow. She has a PhD in molecular biology from the University of Cambridge and is a qualified management accountant (CGMA).

Lord Prior of Brampton


University College London Hospitals NHS Foundation Trust

Lord Prior started as Chairman of UCLH NHS Foundation Trust in January 2018, taking over from Richard Murley.

Lord Prior was educated at Charterhouse School and Pembrooke College, Cambridge where he gained an exhibition and MA in Law. He worked for Lehman Brothers and Lazard Freres in New York training as an investment banker and qualified as a barrister in 1976, becoming a member of Gray’s Inn. He has held a number of senior positions within the industrial sector, including British Steel and was also elected MP for North Norfolk in 1997 and served until 2001.

He has served as Chairman of Norfolk & Norwich University Hospitals NHS Foundation Trust and also Chairman of the Care Quality Commission.

In 2015, he was appointed Parliamentary Under Secretary of State for Health and created a Life Peer. In December 2016, he was appointed as Parliamentary Under Secretary of State at the Department of Business, Energy & Industrial Strategy stepping down from this role in December 2017 to join UCLH.

In April 2018, he was appointed as Senior Advisor to Lazard Financial Advisory and will provide strategic counsel to Lazard and their clients, particularly in the healthcare sector.

Dr John Kelly

Head of Business Development


PhD from the Department of Thoracic Medicine, National Heart and Lung Institute, London, a BSc (Hons) Pharmacology from King’s College London and a BSc (Gen) Pharmacology and Chemistry from University College Dublin.5 years Postdoctoral at Cancer Research UK, (previously Imperial Cancer Research Fund), London, UK and Department of Pharmacology, University of South Alabama College of Medicine, Mobile, Alabama, USA.

Joined MRC Technology (now LifeArc) in October 2000:
Current position: Head of Business Development. Leading team, focus is on identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group, alliances between our drug discovery group and biotech/Pharma and the licensing of mature programmes to industry. Responsible for several licensing and antibody humanisation deals between LifeArc and Pharma/Biotech.

John will explain more about collaboration and funding opportunities with LifeArc.

Dr Richard Butt

Chief Executive Officer

Apollo Therapeutics

Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). Apollo provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.
At the BIA Networking Lunch in Stevenage, Dr. Richard But, CEO of Apollo Therapeutics, will update on progress in developing and executing a broad portfolio of therapeutic approaches.